Ibex Medical Analytics

A decade of clinical AI leadership. Another record-performing quarter. A clear trajectory toward doubling revenue. Ibex Medical Analytics is proud to celebrate 10 years of pioneering clinical innovation. But we aren't just reflecting on a decade of validation—we are accelerating forward. Ahead of the European Congress of Pathology (ECP) 2026, we are thrilled to announce the release of Ibex Lymph Node (RUO). This milestone completes the industry’s most comprehensive, clinical-grade Breast AI Suite. Digital laboratories now have a unified workspace designed to combat severe pathologist shortages, mounting workloads, and increasingly complex cases, seamlessly transitioning across: Biopsy & excision review (H&E), standardized IHC scoring (including HER2, ER, PR, and Ki67) and advanced metastases detection in lymph nodes Our strong commercial momentum is also driving a natural expansion into biopharma. We are leveraging this proven, clinical-grade foundation to expand our partnerships with leading pharmaceutical organizations, helping to accelerate biomarker discovery and drug development to bring targeted therapies to patients faster. Heading to #ECP2026? Come celebrate 10 years of pathology innovation with the Ibex team, explore our unmatched clinical evidence, and see the completed Breast AI Suite in action at Booth #330! Read the full announcement here: https://lnkd.in/exFXf9Cs #DigitalPathology #PrecisionOncology #Biopharma #ClinicalAI #ECP2026 #HealthTech

In oncology clinical trials, subjective visual scoring of immunohistochemistry (IHC) biomarkers is a major risk factor for drug development failure. Classifying hundreds of thousands of cells based on subtle color gradients is inherently subjective, resulting in high inter-observer and intra-observer variability that can mistakenly exclude eligible patients or skew drug efficacy data. In a recent interview with Technology Networks, our Co-Founder, President, and GM (US), Joseph (Yossi) Mossel, discusses how AI-driven pathology is transforming biomarker development for biopharma. With the rapid rise of targeted therapies like Antibody-Drug Conjugates (ADCs), accurate and consistent IHC biomarker scoring is more critical than ever. By leveraging Ibex’s Biopharma Services and integrating clinical-grade AI into their biomarker development process, biopharma partners gain a highly consistent, reproducible "digital gold standard" that de-risks trials and ensures analytical robustness. Read the full interview here: https://lnkd.in/eqgcUdSn #transitionalresearch #biopharma #precisiondiagnostics #biomarkers

L'IA en anatomopathologie de routine : témoignages directs de l'Institut Curie en France. Nous sommes heureux de partager une présentation exclusive du Professeur Anne Vincent-Salomon, Chef du Département d'Anatomopathologie du prestigieux Institut Curie à Paris, en France. Filmée lors de notre récent symposium à #USCAP2026, cette session offre un aperçu de première main de la façon dont les grandes institutions cliniques françaises sont pionnières dans la transformation numérique. Le Dr Vincent-Salomon propose une vue d'ensemble complète de la transition de l'Institut Curie vers un flux de travail entièrement numérique, ainsi que de la mise en œuvre clinique courante et à haut volume d'Ibex Prostate et Ibex Breast sur des cohortes de patients français. 📌 Points clés : Évaluation en conditions réelles : Analyse de biopsies guidée par l'IA, déployée dans des parcours cliniques français actifs. Quantification automatisée : Scoring précis de biomarqueurs clés, notamment HER2, Ki67, RE et RP. Co-pilote diagnostique : Amélioration de la sécurité des patients et renforcement de la reproductibilité inter-observateurs au sein des équipes de pathologie. Comme le souligne le Dr Vincent-Salomon, si les modèles économiques mondiaux liés à l'IA continuent d'évoluer, l'utilité clinique de ces outils pour élever le niveau de qualité des soins aux patients est d'ores et déjà solidement établie dans les principaux centres d'oncologie français. Regardez la présentation complète ici : https://lnkd.in/dMS9rWcx

One of the biggest themes in the conversations with lab executives and pathologists is the need for immediate operational benefits. We can’t wait five years for efficiency; we need it today. Our latest prospective study across five NHS hospital networks demonstrates how #AI doesn't just improve accuracy, but changes the entire math on lab productivity. I’m seeing more and more labs refer to AI as a "must-have" rather than a "nice-to-have" to manage the increasing complexity of breast cancer cases. See how these five NHS hospital networks achieved high diagnostic accuracy and immediate operational benefits for their busy labs: https://lnkd.in/eS9zJB6F #LabManagement #Pathology #Efficiency #HealthTech #USCAP2026 #DigitalPathology #CancerResearch #MedTech #BreastCancer #Innovation #BreastPathology #NHS #ClinicalEvidence #ClinicalAI NHS England NHS Wales

Is your backlog hiding high-risk GI cases? In many systems, gastric biopsies classified as "routine" can face wait times exceeding 60 working days - a delay that can significantly impact patient outcomes. This NHS Wales based study, authored by Dr. Muhammad Aslam, Angie Phillips & team at Betsi Cadwaladr University Health Board, proves how Ibex Medical Analytics AI-driven triage can accurately identify high-risk cases currently hidden in backlogs. By prioritizing these cases for earlier review, we are helping clinicians move from "waiting" to "treating." I've been speaking with many lab directors lately about backlogs, and this study provides a real blueprint for the solution. The full breakdown of the NHS Wales diagnostic transformation is worth a read: https://lnkd.in/ek--K6sV #HealthTech #Pathology #ClinicalAI #Innovation #USCAP2026 #DigitalPathology #NHS #CancerCare #MedTech #AI #NHSWales

Institut Curie pathologists “addicted” to Ibex! ☺️ Dr. Anne Vincent-Salomon shares their experience of Ibex Medical Analytics reporting outstanding quality at #USCAP2026 USCAP - United States and Canadian Academy of Pathology